stockrow
Friday 6 November 2026
Export AEON’s income statement to Excel — free account
AEON Biopharma, Inc.
AEON Healthcare Biotechnology
- EPS
- +96.7%
- Free cash flow
- −76.9%
- Total debt
- −88.4%
Quarter to June 2026, against a year earlier
0.18
0.02
+12.50%
Follow AEON
Alert me
AEON Biopharma, Inc. (AEON) P/E ratio
AEON Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 76.5× (May 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 76.5×
Ten-year median
0.0×
Current reading's percentile
56
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AEON AEON Biopharma, Inc. | n/m |
| HIND Vyome Holdings, Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| GUTS Fractyl Health, Inc. compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| DARE Dare Bioscience, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.1× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)